CL2020002225A1 - Uso de anticuerpos anti-il-36r para el tratamiento de la enfermedad inflamatoria intestinal - Google Patents

Uso de anticuerpos anti-il-36r para el tratamiento de la enfermedad inflamatoria intestinal

Info

Publication number
CL2020002225A1
CL2020002225A1 CL2020002225A CL2020002225A CL2020002225A1 CL 2020002225 A1 CL2020002225 A1 CL 2020002225A1 CL 2020002225 A CL2020002225 A CL 2020002225A CL 2020002225 A CL2020002225 A CL 2020002225A CL 2020002225 A1 CL2020002225 A1 CL 2020002225A1
Authority
CL
Chile
Prior art keywords
treatment
antibodies
inflammatory bowel
bowel disease
ibd
Prior art date
Application number
CL2020002225A
Other languages
English (en)
Inventor
Wulf Otto Boecher
Janine Lamar
Steven John Padula
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2020002225A1 publication Critical patent/CL2020002225A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Rehabilitation Therapy (AREA)
  • General Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere al tratamiento de la enfermedad inflamatoria intestinal (IBD) con anticuerpos anti-IL36R.
CL2020002225A 2018-03-14 2020-08-28 Uso de anticuerpos anti-il-36r para el tratamiento de la enfermedad inflamatoria intestinal CL2020002225A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862642641P 2018-03-14 2018-03-14
US201862729511P 2018-09-11 2018-09-11
US201862743778P 2018-10-10 2018-10-10

Publications (1)

Publication Number Publication Date
CL2020002225A1 true CL2020002225A1 (es) 2021-01-22

Family

ID=65995838

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002225A CL2020002225A1 (es) 2018-03-14 2020-08-28 Uso de anticuerpos anti-il-36r para el tratamiento de la enfermedad inflamatoria intestinal

Country Status (13)

Country Link
US (3) US20190284273A1 (es)
EP (2) EP3765515A2 (es)
JP (1) JP2021517577A (es)
KR (1) KR20200131303A (es)
CN (1) CN111868090A (es)
AU (1) AU2019234478A1 (es)
BR (1) BR112020016401A2 (es)
CA (1) CA3090421A1 (es)
CL (1) CL2020002225A1 (es)
IL (1) IL277217A (es)
MX (1) MX2020009540A (es)
PH (1) PH12020551443A1 (es)
WO (1) WO2019177883A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115925932A (zh) 2015-04-15 2023-04-07 安奈普泰斯生物有限公司 针对白细胞介素36受体（il-36r）的抗体
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
JP2021517577A (ja) * 2018-03-14 2021-07-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 炎症性腸疾患の処置のための抗ｉｌ−３６ｒ抗体の使用
BR112020016738A2 (pt) 2018-03-14 2020-12-15 Boehringer Ingelheim International Gmbh Uso de anticorpos anti-il-36r para o tratamento de psoríase pustular generalizada
AU2019306217B2 (en) 2018-07-16 2024-01-25 Regeneron Pharmaceuticals, Inc. Anti-IL36R antibodies
IL286100B2 (en) 2019-03-08 2024-12-01 Boehringer Ingelheim Int Anti-il-36r antibody formulations
BR112022026999A2 (pt) 2020-07-17 2023-01-24 Boehringer Ingelheim Int Anticorpos anti-il-36r para tratamento de dermatoses neutrofílicas
WO2022026829A1 (en) 2020-07-30 2022-02-03 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for skin toxicity
EP4188441A1 (en) 2020-07-30 2023-06-07 AnaptysBio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for ichthyosis
CN112094349B (zh) * 2020-11-04 2021-02-09 上海华奥泰生物药业股份有限公司 靶向于白介素36r的抗体及其制备方法和应用
WO2022150644A1 (en) 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for acne
WO2022150642A1 (en) 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for hidradenitis suppurativa
JP2024513706A (ja) * 2021-04-01 2024-03-27 メディビーコン，インク． 粘膜治癒をモニタリングする方法
US20230049147A1 (en) * 2021-08-13 2023-02-16 Boehringer Ingelheim International Gmbh Anti-il-36r antibodies for the treatment of a fibrotic condition

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO2009040602A1 (en) 2007-09-25 2009-04-02 Becton Dickinson France Autoinject0r with deactivating means moveable by a safety shield
SI3536710T1 (sl) * 2011-11-16 2026-04-30 Boehringer Ingelheim International Gmbh Protitelesa proti IL-36R
CH705992A2 (de) 2012-10-11 2013-06-14 Tecpharma Licensing Ag Injektionsvorrichtung.
CN115925932A (zh) * 2015-04-15 2023-04-07 安奈普泰斯生物有限公司 针对白细胞介素36受体（il-36r）的抗体
CN112870489B (zh) 2015-04-24 2022-12-06 艾斯曲尔医疗公司 药剂输送装置的子组件和药剂输送装置
CH711066A2 (de) 2015-05-13 2016-11-15 Tecpharma Licensing Ag Verbesserte Injektionsvorrichtung.
JP2020512344A (ja) * 2017-03-27 2020-04-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ−３６ｒ抗体併用治療
JP2021517577A (ja) * 2018-03-14 2021-07-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 炎症性腸疾患の処置のための抗ｉｌ−３６ｒ抗体の使用
IL286100B2 (en) * 2019-03-08 2024-12-01 Boehringer Ingelheim Int Anti-il-36r antibody formulations

Also Published As

Publication number Publication date
CN111868090A (zh) 2020-10-30
EP4183804A1 (en) 2023-05-24
US20240018232A1 (en) 2024-01-18
MX2020009540A (es) 2020-10-05
WO2019177883A2 (en) 2019-09-19
PH12020551443A1 (en) 2021-08-23
JP2021517577A (ja) 2021-07-26
CA3090421A1 (en) 2019-09-19
BR112020016401A2 (pt) 2020-12-15
WO2019177883A3 (en) 2020-03-26
IL277217A (en) 2020-10-29
EP3765515A2 (en) 2021-01-20
US20210061901A1 (en) 2021-03-04
AU2019234478A1 (en) 2020-08-20
US20190284273A1 (en) 2019-09-19
KR20200131303A (ko) 2020-11-23

Similar Documents

Publication Publication Date Title
CL2020002225A1 (es) Uso de anticuerpos anti-il-36r para el tratamiento de la enfermedad inflamatoria intestinal
AR132627A2 (es) Procesos para preparar compuestos intermediarios de utilidad para sintetizar compuestos de carbamoilpiridona policíclicos
JOP20200300A1 (ar) أجسام مضادة لـ il-11ra
CL2018000829A1 (es) Anticuerpos anti-cd19 humano con alta afinidad
CO2018010538A2 (es) Anticuerpos específicos del receptor de poliovirus humano (rvp)
CL2020002540A1 (es) Anticuerpos anti-hla-g y utilización de los mismos
GT201600215A (es) Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4
DOP2018000010A (es) Inhibidores peptídicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias
CO2017012974A2 (es) Anticuerpos de unión a tau
CL2017002237A1 (es) Proteína de unión de il-18 (il-18bp) y anticuerpos en enfermedades inflamatorias.
EA201591285A1 (ru) Иммунотерапия тау
CL2017001090A1 (es) Inmunoglobulinas hetero-diméricas de redireccionamiento de células t cd3/cd38 y sus métodos de producción
EA201891202A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891201A1 (ru) Композиции, содержащие бактериальные штаммы
CL2019003270A1 (es) Carboxamidas de octa hidrofenantreno - bis y conjugados de proteína.
EA201890049A1 (ru) Композиции, содержащие бактериальные штаммы
CO2017012971A2 (es) Anticuerpos de unión a tau
BR112016014731A2 (pt) Anticorpos anti-baff
MX2022015250A (es) Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn.
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
UA123202C2 (uk) Антитіло до тау-білка і його застосування
CL2019003557A1 (es) Anticuerpos anti-trkb.
EA201790879A1 (ru) 6-альфа-алкил-3,7-дионовые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
EA201790885A1 (ru) 6α-АЛКИЛ-6,7-ДИОНОВЫЕ СТЕРОИДЫ В КАЧЕСТВЕ ПРОМЕЖУТОЧНЫХ СОЕДИНЕНИЙ ДЛЯ ПОЛУЧЕНИЯ СТЕРОИДНЫХ МОДУЛЯТОРОВ FXR
EA201992317A1 (ru) Композиции и способы для диагностики рака легких